<\/p>\n
172 economies are now engaged in discussions to potentially participate in COVAX, a global initiative aimed at working with vaccine manufacturers to provide countries worldwide equitable access to safe and effective vaccines,
\n once they are licensed and approved. COVAX currently has the world\u2019s largest and most diverse COVID-19 vaccine portfolio – including nine candidate vaccines, with a further nine under evaluation and conversations underway with other ><\/p>\n
COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, is co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance, and the World Health Organization (WHO) \u2013 working in partnership with
\n developed and developing country vaccine manufacturers. It is the only global initiative that is working with governments and manufacturers to ensure COVID-19 vaccines are available worldwide to both higher-income and lower-><\/p>\n
In order to be able to secure enough doses of vaccines to protect the most vulnerable populations, such as health workers and the elderly, the next step for the partnership is to confirm potential self-financing participants\u2019 intent to participate \u201cEqual access to a COVID-19 vaccine is the key to beating the virus and paving the way for recovery from the pandemic,\u201d said Stefan L\u00f6fven, Prime Minister of Sweden. \u201cThis cannot be a race with a few winners, and the COVAX Facility The COVAX Facility is a Gavi-coordinated pooled procurement mechanism for new COVID-19 vaccines, through which COVAX will ensure fair and equitable access to vaccines for each participating economy, using an allocation framework currently being formulated The success of COVAX hinges not only on countries signing up to the COVAX Facility, but also filling key funding gaps for both COVAX R&D work and a mechanism to support participation of lower-income economies in the COVAX Facility. <\/p>\n \u201cCOVID-19 is an unprecedented global health challenge that can only be met with unprecedented cooperation between governments, researchers, manufacturers and multilateral partners,\u201d said Dr Tedros Adhanom Ghebreyesus, Director-General of WHO. CEPI is leading COVAX vaccine research and development work, which aims to develop three safe and effective vaccines which can be made available to countries participating in the COVAX Facility. Nine candidate vaccines are currently being supported by A further nine candidates vaccines which complement the current CEPI portfolio are currently being evaluated for inclusion in COVAX. \u00a0Furthermore, COVAX will consider procuring vaccines that complement the portfolio from any producer in the world; \u201cIn the scramble for a vaccine, countries can act alone \u2013 creating a few winners, and many losers – or they can come together to participate in COVAX, an initiative which is built on enlightened self-interest but also equity, leaving no country A collaboration between Serum Institute of India (SII), Gavi and the Bill & Melinda Gates Foundation announced earlier this month<\/a> will ensure up to 100 million doses of AstraZeneca or Novavax\u2019s candidate vaccines, if successful, will be available to low- and middle-income economies through the COVAX Facility at just US$ 3 per dose. The arrangement also provides an option In addition, in June Gavi\u00a0launched<\/a>\u00a0the COVAX Advance Market Commitment (AMC),\u00a0a financing instrument aimed at\u00a0supporting the participation of 80 higher-income economies, which would finance the vaccines from their own public finance budgets, have so far submitted Expressions of Interest ahead of the 31 of August deadline for confirmation of intent to participate. They will partner with 92 low- \u201cThe momentum we are witnessing behind this unprecedented global effort means there could be light at the end of the tunnel: A vaccine is our best route to ending the acute phase of the pandemic and the COVAX effort is the best way to get there,\u201d The COVAX Facility is coordinated by Gavi, the Vaccine Alliance, and forms a key part of COVAX \u2013 the vaccines pillar of the ACT Accelerator, a ground-breaking global collaboration involving vaccine manufacturers to accelerate the development, production, The goal of COVAX is by the end of 2021 to deliver two billion doses of safe, effective vaccines that have passed regulatory approval and\/or WHO prequalification. These vaccines will be offered equally to all participating countries, proportional to their \u00a0<\/p>\n ———————————————<\/p>\n Notes to editors<\/strong><\/p>\n The full list of CEPI-supported candidate vaccines is as follows:<\/p>\n The nine candidate vaccines that are currently being evaluated for inclusion in the COVAX Facility include two from China, two from the United States of America, one from the People’s Republic of Korea, one from the United Kingdom of Great Britain and Northern Ireland and one global, multi-manufacture partnership. Two of these are in Phase I trials, two are tech transfers and the remainder are at the discovery stage.<\/p>\n The 80 countries that have submitted expressions of interest to the Gavi-coordinated COVAX Facility include 43 that have agreed to be publicly named: Andorra, Argentina, Armenia, Botswana, Brazil, Canada, Chile, Colombia, Croatia, Czech Republic, Dominican Republic, Estonia, Finland, Greece, Iceland, Iraq, Ireland, Israel, Japan, Jordan, Kuwait, Lebanon, Luxembourg, Mauritius, Mexico, Monaco, Montenegro, New Zealand, North Macedonia, Norway, Palau, Portugal, Qatar, the People’s Republic of Korea, San Marino, Saudi Arabia, Seychelles, Singapore, South Africa, Switzerland, United Arab Emirates, United Kingdom of Great Britain and Northern Ireland and Venezuela. In July the Gavi Board agreed<\/a> on the 92 economies that will be supported the COVAX Advance Market Commitment (AMC). The full list is as follows:<\/p>\n Gavi, the Vaccine Alliance is a public-private partnership that helps vaccinate half the world\u2019s children against some of the world\u2019s deadliest diseases. Since its inception in 2000, Gavi has helped to immunise a whole generation \u2013 over 760 million children \u2013 and prevented more than 13 million deaths, helping to halve child mortality in 73 developing countries. Gavi also plays a key role in improving global health security by supporting health systems as well as funding global stockpiles for Ebola, cholera, meningitis and yellow fever vaccines.\u00a0\u00a0After two decades of progress, Gavi is now focused on protecting the next generation and\u00a0reaching the unvaccinated children still being left behind, employing innovative finance and the latest technology \u2013 from drones to biometrics \u2013 to save millions more lives, prevent outbreaks before they can spread and help countries on the road to self-sufficiency.\u00a0Learn more at\u00a0www.gavi.org<\/a>\u00a0and connect with us on\u00a0Facebook<\/a>\u00a0and\u00a0Twitter<\/a>.<\/p>\n The Vaccine Alliance brings together developing country and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry, technical agencies, civil society, the Bill & Melinda Gates Foundation and other private sector partners. View the full list of donor governments and other leading organizations that fund Gavi\u2019s work\u00a0here<\/a>.<\/p>\n About CEPI<\/strong> CEPI is an innovative partnership between public, private, philanthropic, and civil\u00a0organisations, launched at Davos in 2017, to develop vaccines to stop future epidemics. CEPI has moved with great urgency and in coordination with WHO in response to the emergence of COVID-19. CEPI has initiated\u00a0nine\u00a0partnerships to develop vaccines against the novel coronavirus. The\u00a0programmes\u00a0are leveraging rapid response platforms already supported by CEPI as well as new partnerships. <\/p>\n Before the emergence of COVID-19, CEPI\u2019s priority diseases included Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus,\u00a0Nipah\u00a0virus, Rift Valley Fever and Chikungunya virus. CEPI also invested in platform technologies that can be used for rapid vaccine and immunoprophylactic development against unknown pathogens (Disease X).\u00a0\u00a0<\/p>\n About WHO<\/strong><\/p>\n The World Health Organization provides global leadership in public health within the United Nations system. Founded in 1948, WHO works with\u00a0194 Member States, across six regions and from more than 150 offices,\u00a0to promote health, keep the world safe and serve the vulnerable. Our goal for 2019-2023 is to ensure that a billion more people have universal health coverage, to protect a billion more people from health emergencies, and provide a further billion people with better health and wellbeing.<\/p>\n For updates on COVID-19 and public health advice to protect yourself from coronavirus, visit\u00a0www.who.int<\/a>\u00a0and follow WHO on\u00a0Twitter<\/a>,\u00a0Facebook<\/a>,\u00a0Instagram<\/a>,\u00a0LinkedIn<\/a>,\u00a0TikTok<\/a>,\u00a0Pinterest<\/a>,\u00a0Snapchat<\/a>,\u00a0YouTube<\/a><\/p>\n<\/div>\n
\n by 31 August and to turn these into binding commitments to join the COVID-19 Vaccine Global Access Facility (COVAX Facility) by 18th<\/sup> of September, with first upfront payments to follow thereafter, and no later than 9th<\/sup> of October 2020.<\/p>\n
\n is an important part of the solution \u2013 making sure all countries can benefit from access to the world\u2019s largest portfolio of candidates and fair and equitable distribution of vaccine doses.\u201d<\/p>\n
\n by WHO. The COVAX Facility will do this by pooling buying power from participating economies and providing volume guarantees across a range of promising vaccine candidates, allowing those vaccine manufacturers whose expertise is essential to large
\n scale production of the new vaccines, to make early, at-risk investments in manufacturing capacity \u2013 providing participating countries and economies with the best chance at rapid access to doses of a successful COVID-19 vaccine. <\/p>\n
\n \u201cBy pooling resources and acting in solidarity through the ACT Accelerator and the COVAX Facility, we can ensure that once a vaccine is available for COVID-19, it\u2019s available equitably to all countries.\u201d<\/p>\n
\n CEPI; seven of which are currently in clinical trials. Governments, vaccine manufacturers (in addition to their own R&D), organizations and individuals have committed US$ 1.4 billion towards vaccine R&D so far, but an additional US$1 billion is urgently needed
\n to continue to move the portfolio forward. <\/p>\n
\n conversations are already underway with a number of additional manufacturers not receiving R&D support from CEPI to procure their vaccines if they are successful. Maximizing the portfolio of vaccines increases the probability of success as individual
\n vaccines historically have a high failure rate.<\/p>\n
\n behind,\u201d said Richard Hatchett, CEO of CEPI. \u201cOnly by taking a global view can we protect those most at risk around the world from the terrible effects of this disease. COVAX can deliver the vaccines that could end the pandemic, but it
\n needs countries to step forward both to join the COVAX Facility, and also to address the serious funding shortfalls, including for R&D. The decisions that are taken now about COVID-19 vaccines have the power to change our future. We must be courageous
\n and ambitious in striving for a multilateral solution.\u201d<\/p>\n
\n to secure additional doses if COVAX sees a need for it. Separate agreements between Gavi, CEPI and AstraZeneca, announced in June, guarantee a further 300 million doses of their candidate vaccine, if successful, for the COVAX Facility.<\/p>\n
\n 92 lower\u00a0and middle\u00a0income economies<\/a> in the COVAX Facility. The\u00a0COVAX\u00a0AMC\u00a0has raised\u00a0more than\u00a0US$ 600 million\u00a0against an initial target of securing US$ 2 billion\u00a0seed funding from sovereign\u00a0donors
\n as well as\u00a0philanthropy and\u00a0the private sector,\u00a0needed by the end of 2020.\u00a0Funding the COVAX AMC will be critical to ensuring ability to pay is not a barrier to accessing COVID-19 vaccines, a situation which would leave\u00a0the
\n majority of\u00a0the world unprotected, with the pandemic and its impact continuing unabated.\u00a0\u00a0<\/p>\n
\n and middle-income countries that will be supported by the AMC if it meets its funding targets. Together, this group of 172 countries represents more than 70% of the world\u2019s population. Among the group are representatives from every continent
\n and more than half of the world\u2019s G20 economies.<\/p>\n
\n said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance. \u201cFor higher-income countries it represents a win-win: not only will you be guaranteed access to the world\u2019s largest portfolio of vaccines, you will also be negotiating as part of
\n a global consortium, bringing down prices and ensuring truly global access. Signing up to the COVAX Facility gives each country its best chance at protecting the most vulnerable members of their populations \u2013 which in turn gives the world its
\n best chance at mitigating the toll this pandemic has taken on individuals, communities and the global economy. To make this end-to-end vision a reality, we need countries to make end-to-end commitments: funding R&D, signing up to the Facility,
\n and supporting the COVAX AMC.\u201d<\/p>\n
\n and equitable access to COVID-19 tests, treatments, and vaccines. The overall aim of COVAX is to accelerate the development and manufacture of COVID-19 vaccines, and to guarantee fair and equitable access for every country in the world. It will achieve
\n this by sharing the risks associated with vaccine development, and where necessary investing in manufacturing upfront so vaccines can be deployed at scale as soon as they are proven to be safe and effective, and pooling procurement and purchasing
\n power to achieve sufficient volumes to end the acute phase of the pandemic by 2021.<\/p>\n
\n populations, initially prioritising healthcare workers then expanding to cover vulnerable groups, such as the elderly and those with pre-existing conditions. Further doses will then be made available based on country need, vulnerability and COVID-19
\n threat. The COVAX Facility will also maintain a buffer of doses for emergency and humanitarian use, including dealing with severe outbreaks before they spiral out of control.\u00a0<\/p>\n\n
\n
About Gavi, the Vaccine Alliance<\/strong><\/p>\n